Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking NewAmsterdam Pharma’s quest to bring obicetrapib—its once-daily oral CETP inhibitor—from Phase 3 trials to market means wading through pages of dosing data, milestone payments, and risk factors. If you have ever skimmed a single paragraph in a 300-page report searching for an LDL-C result, you know the challenge.
Stock Titan solves it. Our AI-powered summaries turn every NewAmsterdam Pharma SEC filings explained simply: Form 4 alerts arrive the moment executives submit NewAmsterdam Pharma Form 4 insider transactions real-time; 10-Q breakdowns highlight R&D spend and cash runway in the latest NewAmsterdam Pharma quarterly earnings report 10-Q filing; and the full NewAmsterdam Pharma annual report 10-K simplified is annotated so you can locate pipeline timelines fast.
- NewAmsterdam Pharma insider trading Form 4 transactions with sortable tables of each executive stock move
- NewAmsterdam Pharma earnings report filing analysis that connects trial costs to future dilution risk
- understanding NewAmsterdam Pharma SEC documents with AI—context cards translate biotech jargon into plain English
- NewAmsterdam Pharma proxy statement executive compensation so incentive plans align with cardiovascular outcomes
- NewAmsterdam Pharma 8-K material events explained for sudden data releases, licensing deals, or ATM financings
Whether you’re monitoring NewAmsterdam Pharma executive stock transactions Form 4 before trial readouts or comparing lipid-lowering efficacy across quarters, our expert analysis and real-time EDGAR feed keep every disclosure at your fingertips—no more hunting through footnotes.
NewAmsterdam Pharma (NAMS) filed its Q3 2025 10‑Q, reporting revenue of $348 thousand and a net loss of $72.0 million. Operating expenses totaled $55.5 million, driven by R&D $31.0 million and SG&A $24.5 million. Other items included a $23.8 million loss from warrant fair value changes and $6.7 million of interest income.
Liquidity remains strong with $756.0 million in cash, cash equivalents and marketable securities as of September 30, 2025. During the nine months, the company recognized $16.1 million related to development cost contributions under its Menarini license and recorded initial supply revenue of $348 thousand after signing a Menarini Supply Agreement on August 12, 2025. On August 18, 2025, the EMA validated MAAs for obicetrapib 10 mg monotherapy and the obicetrapib + ezetimibe FDC. The PREVAIL outcomes trial completed enrollment in April 2024 and could conclude as early as the end of 2026 based on minimum follow‑up and event targets.
NewAmsterdam Pharma (NAMS) furnished an update on November 5, 2025, announcing corporate updates and financial results for the quarter ended September 30, 2025. The company also posted an updated corporate investor presentation on its website.
Both the press release and the investor presentation were furnished as Exhibits 99.1 and 99.2, respectively, and are not deemed filed under the Exchange Act or incorporated by reference, except as expressly stated in future filings.
James N. Topper, a director of NewAmsterdam Pharma Co N.V. (ticker: NAMSW), reported a purchase on Form 4. The filing shows a transaction on 09/15/2025 acquiring 660 ordinary shares at a weighted average price of $23.6953. The filing lists two holdings following the reported transaction: 3,028,524 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. Footnotes state the reported price is a weighted average from multiple purchases priced between $23.46 and $23.75. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Topper on 09/17/2025.
FAQ
What is the current stock price of NewAmsterdam Pharma Company N.V (NAMS)?
What is the market cap of NewAmsterdam Pharma Company N.V (NAMS)?
